We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PD-1 / PD-L1 Antibodies

PD-1 / PD-L1 antibodies block the programmed cell death protein 1 (PD-1) checkpoint on T cells or its ligand PD-L1. Binding of PD-L1 on tumor or antigen-presenting cells to PD-1 suppresses T-cell activation, so blocking either partner restores effector function in co-culture and tumor models. Anti-PD-1 antibodies in this group include pembrolizumab, nivolumab, cemiplimab, dostarlimab, tislelizumab and toripalimab. Atezolizumab, durvalumab and avelumab bind PD-L1 instead, and avelumab retains antibody-dependent cell-mediated cytotoxicity (ADCC). The antibodies serve as reference reagents in checkpoint blockade assays, receptor occupancy studies and combination experiments.

Items 76-76 of 76

  • Anti-PDCD1/PD-1/CD279 Antibody — antibody illustration
    Cat. No.
    AT1514

    Anti-PDCD1/PD-1/CD279 Antibody

    The Anti-PDCD1/PD-1/CD279 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the PDCD1/PD-1/CD279 protein. This antibody is constructed with a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody serves as a crucial tool in the study of immune checkpoint regulation and has potential applications in immunotherapy research.

    In stock View Details
    1 mg
    $450.00
    5 mg
    $1,400.00
    All 3 sizes

Items 76-76 of 76

Added to your cart

View Cart Checkout

    Loading...